Literature DB >> 975020

Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells.

B Drewinko, T L Loo, B Brown, J A Gottlieb, E J Freireich.   

Abstract

Adriamycin was paired with 12 other chemotherapeutic drugs in a search for possible synergistic pairs. Cell lethality was investigated by the colony-formation method utilizing a long-term human lymphoma cell line. Addative effects were noted with CCNU, ara-C, prednisolone, DDP, VP-16, and Yoshi, and mild synergistic effects with BLEO and CS. Adriamycin reduced the killing ability of BCNU and MeCCNU when applied simultaneously. This antagonistic effect was canceled by sequential incubation with each drug. It appears that no significant synergism can be expected by simultaneous pairing of adriamycin with some currently available chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 975020

Source DB:  PubMed          Journal:  Cancer Biochem Biophys        ISSN: 0305-7232


  36 in total

1.  Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.

Authors:  Sameer Mirza; Gayatri Sharma; Pranav Pandya; Ranju Ralhan
Journal:  Mol Cell Biochem       Date:  2010-05-09       Impact factor: 3.396

2.  Photothermal enhancement of chemotherapy mediated by gold-silica nanoshell-loaded macrophages: in vitro squamous cell carcinoma study.

Authors:  Steen J Madsen; En-Chung Shih; Qian Peng; Catherine Christie; Tatiana Krasieva; Henry Hirschberg
Journal:  J Biomed Opt       Date:  2016-01       Impact factor: 3.170

3.  Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines.

Authors:  Marlon S Mathews; Van Vo; En-Chung Shih; Genesis Zamora; Chung-Ho Sun; Steen J Madsen; Henry Hirschberg
Journal:  J Environ Pathol Toxicol Oncol       Date:  2012       Impact factor: 3.567

4.  Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits.

Authors:  G M Ferron; W J Jusko
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

5.  The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

Authors:  Susan L Holbeck; Richard Camalier; James A Crowell; Jeevan Prasaad Govindharajulu; Melinda Hollingshead; Lawrence W Anderson; Eric Polley; Larry Rubinstein; Apurva Srivastava; Deborah Wilsker; Jerry M Collins; James H Doroshow
Journal:  Cancer Res       Date:  2017-04-26       Impact factor: 12.701

6.  Synergistic chemotherapy by combined moderate hyperthermia and photochemical internalization.

Authors:  Catherine Christie; Stephanie Molina; Jonathan Gonzales; Kristian Berg; Rohit Kumar Nair; Khoi Huynh; Steen J Madsen; Henry Hirschberg
Journal:  Biomed Opt Express       Date:  2016-03-14       Impact factor: 3.732

7.  Synergistic Anticancer Action of Lysosomal Membrane Permeabilization and Glycolysis Inhibition.

Authors:  Milica Kosic; Katarina Arsikin-Csordas; Verica Paunovic; Raymond A Firestone; Biljana Ristic; Aleksandar Mircic; Sasa Petricevic; Mihajlo Bosnjak; Nevena Zogovic; Milos Mandic; Vladimir Bumbasirevic; Vladimir Trajkovic; Ljubica Harhaji-Trajkovic
Journal:  J Biol Chem       Date:  2016-09-01       Impact factor: 5.157

8.  Pharmacologic studies of anticancer drugs with the human tumor stem cell assay.

Authors:  D S Alberts; S E Salmon; H S Chen; T E Moon; L Young; E A Surwit
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Modeling of tumor growth and anticancer effects of combination therapy.

Authors:  Gilbert Koch; Antje Walz; Gezim Lahu; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-04-22       Impact factor: 2.745

10.  Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.

Authors:  Mengyao Li; Hanqing Li; Xiaoliang Cheng; Xipei Wang; Liang Li; Tianyan Zhou; Wei Lu
Journal:  Pharm Res       Date:  2013-01-24       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.